All In Biotech

Drug Trial Radar · NCT04197934

WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU

Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Actual

Start

Dec 20, 2019

Primary completion

Oct 30, 2022

Study completion Feb 6, 2031

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein - a strategy that has led to a lot of benefit in patients with many different cancers. WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers. Funding Source - FDA OOPD

Conditions

  • Anaplastic Astrocytoma, IDH-Wildtype
  • Glioblastoma, IDH-Wildtype
  • Metastatic Lung Non-Small Cell Carcinoma
  • Metastatic Malignant Neoplasm in the Central Nervous System
  • Stage IV Lung Cancer AJCC v8

Interventions

  • Biospecimen Collection - blood samplesProcedure

    Undergo collection of blood samples

  • Biospecimen Collection - CSF samplesProcedure

    Undergo collection of CSF samples

  • Computed TomographyProcedure

    Undergo CT

  • EGFR/EGFRvIII Inhibitor WSD0922-FUDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Therapeutic Conventional SurgeryProcedure

    Undergo surgical resection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase 2 doseTime frame: Up to 28 days

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.